Has Kintin Ng received payments from drug or device companies?

Yes. Drug and device makers reported $3,933 in general payments to Kintin Ng across 66 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kintin Ng did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kintin Ng come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kintin Ng

Internal Medicine · Miami, FLNPI 1316408065

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 32.4% of the total. Reporting peaked in 2024 at $1,453 and has fallen 64.5% since, to $515 in 2025.

$3,933in general payments, 2019–2025

Across 66 payments — averaging $59.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
Insmed, Inc.$332
GSK$241
Abiomed$227
Actelion Pharmaceuticals US, Inc.$186
Stryker$147
plus $2K from 14 others

What the payments were for

Food & beverage$3,79596%
Education$1384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	17	$1,272
Insmed, Inc.	6	$332
GSK	6	$241
Abiomed	3	$227
Actelion Pharmaceuticals US, Inc.	2	$186
Stryker	1	$147
Boehringer Ingelheim	6	$147
Mallinckrodt Hospital Products Inc.	1	$146
Genentech, Inc.	1	$145
Grifols USA, LLC	3	$137
United Therapeutics Corporation	3	$134
Bayer	1	$125
Mylan Specialty L.p.	1	$125
Inspire Medical Systems, Inc.	1	$118
Harmony Biosciences LLC	6	$111
Intuitive Surgical	1	$109
Melinta Therapeutics, LLC	1	$102
Amgen	3	$51
Jazz Pharmaceuticals Inc.	2	$51
Pharming Healthcare, Inc.	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,933 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Other internal medicine in Miami

Haytham ElgammalMiami$2.2M
Richard AguilarMiami$239K
Maria Delgado LelievreMiami$80K
Marlow HernandezMiami$58K
Steven CohnMiami$47K
Joseph PiperatoMiami$45K
Simon AbelsonMiami$44K
Joel Brooks TamayoMiami$42K
Keith RubinFort Lauderdale$2M
Michael SensionFort Lauderdale$1M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →